Industry News
Study Identifies Disease-Specific Targets to Inform Precision Drug Development in Breast Cancer Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster,…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the SNMMI Annual Meeting. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing Oncology research and streamlining clinical trial execution for Sponsors and CROs. Meet with Christopher and Nick at this exciting event…
Read More The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at DIA 2025. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing Oncology research and streamlining clinical trial execution for Sponsors and CROs. Meet with Christopher and Nick at this exciting event and you’ll…
Read More
Excerpt from the Press Release: NEWARK, Del.–(BUSINESS WIRE)–QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalytics and clinical trials, is celebrating its 30-year anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to provide high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS is now recognized as…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the…
Read More
New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) data and results on time without transfusion reliance (TWiTR) provide deeper insights into patient-centric outcomes with RYTELO in LR-MDS…
Read More
Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock Phase 3 program Excerpt from the Press Release: WARRINGTON, Pa., May 22, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or…
Read More
CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer All six responders in the 20 mg/kg cohorts remain on treatment, with four patients on study for…
Read More
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at ASCO 2025. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing Oncology research and streamlining clinical trial execution for Sponsors and CROs. Meet with Christopher and Nick at this exciting event and you’ll…
Read More
Excerpt from the Press Release: WATERTOWN, Mass., May 15, 2025 /PRNewswire/ — Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced the presentation of new preclinical data supporting its in vivo CAR therapy approach in autoimmune diseases during an…
Read More